Clinical Trial Update: Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/2 clinical trial evaluating a cancer lysate vaccine with Montanide ISA-51 VG, with or without the IL-15 super-agonist N-803, as adjuvant thera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cancer lysate vaccine
• Montanide ISA-51 VG (Montanide ISA-51 VG)
• N-803

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma | Phase 1, Phase 2 | Status: SUSPENDED